INTS · Intensity Therapeutics, Inc.

Intensity Therapeutics reported a narrower Q1 2026 net loss of $2.4 million compared to $3.3 million in Q1 2025, primarily due to reduced research and development expenses of $1.2 million versus $2.2 million, stemming from the March 2025 pause in new site activations and patient enrollments in the INVINCIBLE-3 Phase 3 sarcoma study amid funding constraints. Prior to the pause, INVINCIBLE-3 had enrolled 21 patients, and ongoing activities have been maintained at reduced costs with third-party contract research organizations. General and administrative expenses rose slightly to $1.3 million from $1.2 million, driven by a bonus accrual in 2026 absent in 2025, partially offset by lower stock-based compensation and reverse stock split costs. Cash and cash equivalents stood at $10.2 million as of March 31, 2026, supporting plans to resume limited U.S. site enrollments in INVINCIBLE-3 by Q3 2026 and full activations upon additional funding, following a 2025 funding campaign and $60 million ATM facility in March 2026. CEO Lewis H. Bender highlighted progress in INVINCIBLE-4, a Phase 2 TNBC study, where preliminary data showed 71.4% pathological complete response (pCR) in seven patients receiving INT230-6 before standard-of-care (SOC) versus 33% in six SOC-only patients, with 44% fewer grade 3+ adverse events. Full approval from Swissmedic and the Ethics Committee enables Q2 2026 enrollment resumption in Switzerland and potential France initiation in Q2/Q3. Detailed Cohort A results are expected at a future oncology conference. These updates signal potential efficacy and safety advantages for INT230-6 in high-unmet-need indications, with judicious cash management emphasized.